Literature DB >> 17171705

Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice.

Franziska Richter1, Melanie Hamann, Angelika Richter.   

Abstract

It has been hypothesized that exposures to neurotoxic pesticides together with aging and genetic factors increase the risk for developing Parkinson's disease (PD) which is characterized by a progressive degeneration of the nigrostriatal dopaminergic pathway. Chronic treatment with the pesticide rotenone has been reported to induce parkinsonism in rats. Although transgenic mice (but not transgenic rats) are available to investigate the importance of environmental factors in genetically predisposed animals, the effects of chronic rotenone exposure have so far not been examined in intact mice. Therefore, we investigated the effects of chronic exposure to rotenone (2.5 or 4.0-5.0 mg/kg s.c. for 30-45 days) in mice aged 2.5, 5, or 12 months. During the treatment period, the effects on vitality and motor behavior were investigated. Furthermore, the toxicity of rotenone on dopaminergic nigrostriatal neurons and peripheral tissues was examined. In comparison with control mice, rotenone-treated mice had a decreased spontaneous motor activity, but the density of nigral dopaminergic neurons failed to show any significant changes, except for a tendency to decrease in old mice treated with 4 mg/kg. At the tested doses, rotenone caused a moderate hepatic fatty degeneration. The data indicate that rotenone is not able to cause the neuropathological characteristics of PD in mice under these testing paradigms, which were similar to those of the rotenone rat model. Further studies will have to clarify whether genetic mouse models of PD might be more sensitive to the neurotoxic effects of rotenone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17171705     DOI: 10.1002/jnr.21159

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  19 in total

1.  Neuroprotective effect of aqueous extract of Selaginella delicatula as evidenced by abrogation of rotenone-induced motor deficits, oxidative dysfunctions, and neurotoxicity in mice.

Authors:  Girish Chandran
Journal:  Cell Mol Neurobiol       Date:  2013-07-19       Impact factor: 5.046

2.  Rotenone exerts developmental neurotoxicity in a human brain spheroid model.

Authors:  David Pamies; Katharina Block; Pierre Lau; Laura Gribaldo; Carlos A Pardo; Paula Barreras; Lena Smirnova; Daphne Wiersma; Liang Zhao; Georgina Harris; Thomas Hartung; Helena T Hogberg
Journal:  Toxicol Appl Pharmacol       Date:  2018-02-08       Impact factor: 4.219

Review 3.  Behavioral phenotyping of mouse models of Parkinson's disease.

Authors:  Tonya N Taylor; James G Greene; Gary W Miller
Journal:  Behav Brain Res       Date:  2010-03-06       Impact factor: 3.332

4.  Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.

Authors:  Lu Yao; Wenming Li; Hua She; Juan Dou; Leili Jia; Yingli He; Qian Yang; Jinqiu Zhu; Natalie L Cápiro; Douglas I Walker; Kurt D Pennell; Yuanping Pang; Yong Liu; Yifan Han; Zixu Mao
Journal:  J Biol Chem       Date:  2012-08-13       Impact factor: 5.157

5.  α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.

Authors:  Sonia George; Su San Mok; Milawaty Nurjono; Scott Ayton; David I Finkelstein; Colin L Masters; Qiao-Xin Li; Janetta G Culvenor
Journal:  J Mol Neurosci       Date:  2010-05-13       Impact factor: 3.444

6.  Benefits of betanin in rotenone-induced Parkinson mice.

Authors:  Wachiryah Thong-Asa; Sujira Jedsadavitayakol; Suchawalee Jutarattananon
Journal:  Metab Brain Dis       Date:  2021-08-26       Impact factor: 3.584

7.  Nmnat delays axonal degeneration caused by mitochondrial and oxidative stress.

Authors:  Craig Press; Jeffrey Milbrandt
Journal:  J Neurosci       Date:  2008-05-07       Impact factor: 6.167

Review 8.  Model fusion, the next phase in developing animal models for Parkinson's disease.

Authors:  Amy B Manning-Bog; J William Langston
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

9.  Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice.

Authors:  Francisco Pan-Montojo; Oleg Anichtchik; Yanina Dening; Lilla Knels; Stefan Pursche; Roland Jung; Sandra Jackson; Gabriele Gille; Maria Grazia Spillantini; Heinz Reichmann; Richard H W Funk
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.